Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues

ACS Chemical Neuroscience

Volumn 7, Issue 9, 2016, Pages 1241-1254

  Banister, Samuel D ^a,c   Longworth, Mitchell ^a   Kevin, Richard ^b   Sachdev, Shivani ^d   Santiago, Marina ^d   Stuart, Jordyn ^d   Mack, James B C ^e   Glass, Michelle ^f   McGregor, Iain S ^b   Connor, Mark ^d   Kassiou, Michael ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MACQUARIE UNIVERSITY   (Australia)

^e STANFORD UNIVERSITY   (United States)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

AMB; Cannabinoid; JWH 018; MDMB; THC

Indexed keywords

CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; METHYL 2 [1 (4 FLUOROBENZYL) 1H INDAZOLE 3 CARBOXAMIDO] 3 METHYLBUTANOATE; METHYL 2 [1 (4 FLUOROBENZYL) 1H INDAZOLE 3 CARBOXAMIDO] 3,3 DIMETHYLBUTANOATE; METHYL 2 [1 (4 FLUOROBENZYL) 1H INDOLE 3 CARBOXAMIDO] 3 METHYLBUTANOATE; METHYL 2 [1 (4 FLUOROBENZYL) 1H INDOLE 3 CARBOXAMIDO] 3,3 DIMETHYLBUTANOATE; METHYL 2 [1 (5 FLUOROPENTYL) 1H INDAZOLE 3 CABOXAMIDO] 3 METHYLBUTANOATE; METHYL 2 [1 (5 FLUOROPENTYL) 1H INDAZOLE 3 CARBOXAMIDO] 3,3 DIMETHYLBUTANOATE; METHYL 2 [1 (5 FLUOROPENTYL) 1H INDOLE 3 CARBOXAMIDO] 3 METHYLBUTANOATE; METHYL 2 [1 (5 FLUOROPENTYL) 1H INDOLE 3 CARBOXAMIDO] 3,3 DIMETHYLBUTANOATE; METHYL 2 [1 (CYCLOHEXYLMETHYL) 1H INDAZOLE 3 CARBOXAMIDO] 3 METHYLBUTANOATE; METHYL 2 [1 (CYCLOHEXYLMETHYL) 1H INDAZOLE 3 CARBOXAMIDO] 3,3 DIMETHYLBUTANOATE; METHYL 2 [1 (CYCLOHEXYLMETHYL) 1H INDOLE 3 CARBOXAMIDO] 3 METHYLBUTANOATE; METHYL 2 [1 (CYCLOHEXYLMETHYL) 1H INDOLE 3 CARBOXAMIDO] 3,4 DIMETHYLBUTANOATE; METHYL 2 [1 (PENTYL) 1H INDAZOLE 3 CARBOXAMIDO] 3 METHYLBUTANOATE; METHYL 2 [1 (PENTYL) 1H INDAZOLE 3 CARBOXAMIDO] 3,3 DIMETHYLBUTANOATE; METHYL 2 [1 (PENTYL) 1H INDOLE 3 CARBOXAMIDO) 3,3 DIMETHYLBUTANOATE; METHYL 2 [1 (PENTYL) 1H INDOLE 3 CARBOXAMIDO] 3 METHYLBUTANOATE; RIMONABANT; UNCLASSIFIED DRUG; 2-AMINO-3,3-DIMETHYLBUTANOIC ACID; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; 5F-ADB CANNABINOID; ANALGESIC AGENT; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLOHEXANOL DERIVATIVE; INDAZOLE DERIVATIVE; INDOLE; INDOLE DERIVATIVE; METHYL (1-(5-FLUOROPENTYL)-1H-INDAZOLE-3-CARBONYL)VALINATE; METHYL 2-(1-(4-FLUOROBENZYL)-1H-INDAZOLE-3-CARBOXAMIDO)-3-METHYLBUTANOATE; METHYL 2-(1-(CYCLOHEXYLMETHYL)-1H-INDOLE-3-CARBOXAMIDO)-3,3-DIMETHYLBUTANOATE; VALINE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRADYCARDIA; DRUG POTENCY; DRUG SYNTHESIS; HYPOTHERMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BODY TEMPERATURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HEART RATE; HUMAN;

ANALGESICS; ANIMALS; BODY TEMPERATURE; CANNABINOIDS; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; HUMANS; INDAZOLES; INDOLES; RATS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; VALINE;

EID: 84988646117     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/acschemneuro.6b00137     Document Type: Article

References (88)

1. Brandt, S. D., King, L. A., and Evans-Brown, M. (2014) The new drug phenomenon Drug Test. Anal. 6, 587-597 10.1002/dta.1686
2. Auwarter, V., Dresen, S., Weinmann, W., Muller, M., Putz, M., and Ferreiros, N. (2009) 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J. Mass Spectrom. 44, 832-837 10.1002/jms.1558
3. Uchiyama, N., Kikura-Hanajiri, R., Kawahara, N., and Goda, Y. (2009) Identification of a cannabimimetic indole as a designer drug in a herbal product Forensic Toxicol. 27, 61-66 10.1007/s11419-009-0069-y
4. United Nations Office on Drugs and Crime, World Drug Report (2015) (United Nations publication, Sales No. E.15.XI.6).
5. Blakey, K., Boyd, S., Atkinson, S., Wolf, J., Slottje, P. M., Goodchild, K., and McGowan, J. (2016) Identification of the novel synthetic cannabimimetic 8-quinolinyl 4-methyl-3-(1-piperidinylsulfonyl)benzoate (QMPSB) and other designer drugs in herbal incense Forensic Sci. Int. 260, 40-53 10.1016/j.forsciint.2015.12.001
6. Carlsson, A., Lindberg, S., Wu, X., Dunne, S., Josefsson, M., Astot, C., and Dahlen, J. (2015) Prediction of designer drugs: synthesis and spectroscopic analysis of synthetic cannabinoid analogues of 1H-indol-3-yl(2,2,3,3-tetramethylcyclopropyl)methanone and 1H-indol-3-yl(adamantan-1-yl)methanone Drug Test. Anal. 10.1002/dta.1904
7. Kondrasenko, A. A., Goncharov, E. V., Dugaev, K. P., and Rubaylo, A. I. (2015) CBL-2201. Report on a new designer drug: Napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate Forensic Sci. Int. 257, 209-213 10.1016/j.forsciint.2015.08.023
8. McLaughlin, G., Morris, N., Kavanagh, P. V., Power, J. D., Twamley, B., O'Brien, J., Talbot, B., Dowling, G., and Brandt, S. D. (2015) The synthesis and characterization of the 'research chemical' N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide (3,5-AB-CHMFUPPYCA) and differentiation from its 5,3-regioisomer Drug Test. Anal. 10.1002/dta.1864
9. Uchiyama, N., Asakawa, K., Kikura-Hanajiri, R., Tsutsumi, T., and Hakamatsuka, T. (2015) A new pyrazole-carboxamide type synthetic cannabinoid AB-CHFUPYCA [N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide] identified in illegal products Forensic Toxicol. 33, 367-373 10.1007/s11419-015-0283-8
10. Uchiyama, N., Shimokawa, Y., Kikura-Hanajiri, R., Demizu, Y., Goda, Y., and Hakamatsuka, T. (2015) A synthetic cannabinoid FDU-NNEI, two 2-indazole isomers of synthetic cannabinoids AB-CHMINACA and NNEI indazole analog (MN-18), a phenethylamine derivative OH-EDMA, and a cathinone derivative dimethoxy-alpha-PHP, newly identified in illegal products Forensic Toxicol. 33, 244-259 10.1007/s11419-015-0268-7
11. Westphal, F., Sonnichsen, F. D., Knecht, S., Auwarter, V., and Huppertz, L. (2015) Two thiazolylindoles and a benzimidazole: Novel compounds on the designer drug market with potential cannabinoid receptor activity Forensic Sci. Int. 249, 133-147 10.1016/j.forsciint.2015.01.014
12. Jia, W., Meng, X., Qian, Z., Hua, Z., Li, T., and Liu, C. (2016) Identification of three cannabimimetic indazole and pyrazole derivatives, APINACA 2H-indazole analogue, AMPPPCA, and 5F-AMPPPCA Drug Test. Anal. 10.1002/dta.1967
13. Qian, Z., Hua, Z., Liu, C., and Jia, W. (2016) Four types of cannabimimetic indazole and indole derivatives, ADB-BINACA, AB-FUBICA, ADB-FUBICA, and AB-BICA, identified as new psychoactive substances Forensic Toxicol. 34, 133-143 10.1007/s11419-015-0297-2
14. Shevyrin, V., Melkozerov, V., Eltsov, O., Shafran, Y., and Morzherin, Y. (2016) Synthetic cannabinoid 3-benzyl-5-[1-(2-pyrrolidin-1-ylethyl)-1H-indol-3-yl]-1,2,4-oxadiazole. The first detection in illicit market of new psychoactive substances Forensic Sci. Int. 259, 95-100 10.1016/j.forsciint.2015.12.019
15. Huestis, M. A., Gorelick, D. A., Heishman, S. J., Preston, K. L., Nelson, R. A., Moolchan, E. T., and Frank, R. A. (2001) Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716 Arch. Gen. Psychiatry 58, 322-328 10.1001/archpsyc.58.4.322
16. Castaneto, M. S., Gorelick, D. A., Desrosiers, N. A., Hartman, R. L., Pirard, S., and Huestis, M. A. (2014) Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications Drug Alcohol Depend. 144, 12-41 10.1016/j.drugalcdep.2014.08.005
17. Tuv, S. S., Krabseth, H., Karinen, R., Olsen, K. M., Oiestad, E. L., and Vindenes, V. (2014) Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period Accid. Anal. Prev. 62, 26-31 10.1016/j.aap.2013.09.009
18. Andreeva-Gateva, P. A., Nankova, V. H., Angelova, V. T., and Gatev, T. N. (2015) Synthetic cannabimimetics in Bulgaria 2010-2013 Drug Alcohol Depend. 157, 200-204 10.1016/j.drugalcdep.2015.10.019
19. Zawilska, J. B. and Andrzejczak, D. (2015) Next generation of novel psychoactive substances on the horizon-A complex problem to face Drug Alcohol Depend. 157, 1-17 10.1016/j.drugalcdep.2015.09.030
20. Langer, N., Lindigkeit, R., Schiebel, H.-M., Papke, U., Ernst, L., and Beuerle, T. (2016) Identification and quantification of synthetic cannabinoids in "spice-like" herbal mixtures: update of the German situation for the spring of 2015 Forensic Toxicol. 34, 94-107 10.1007/s11419-015-0292-7
21. Schifano, F., Orsolini, L., Duccio Papanti, G., and Corkery, J. M. (2015) Novel psychoactive substances of interest for psychiatry World Psychiatry. 14, 15-26 10.1002/wps.20174
22. Costain, W. J., Tauskela, J. S., Rasquinha, I., Comas, T., Hewitt, M., Marleau, V., and Soo, E. C. (2016) Pharmacological characterization of emerging synthetic cannabinoids in HEK293T cells and hippocampal neurons Eur. J. Pharmacol. 786, 234-245 10.1016/j.ejphar.2016.05.040
23. Frinculescu, A., Lyall, C. L., Ramsey, J., and Miserez, B. (2016) Variation in commercial smoking mixtures containing third-generation synthetic cannabinoids Drug Test. Anal. 10.1002/dta.1975
24. Gerostamoulos, D., Elliott, S., Walls, H. C., Peters, F. T., Lynch, M., and Drummer, O. H. (2016) To Measure or Not to Measure? That is the NPS Question J. Anal. Toxicol. 40, 318-320 10.1093/jat/bkw013
25. Hess, C., Schoeder, C. T., Pillaiyar, T., Madea, B., and Müller, C. E. (2016) Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice Forensic Toxicol. 34, 329 10.1007/s11419-016-0320-2
26. Odoardi, S., Romolo, F. S., and Strano-Rossi, S. (2016) A snapshot on NPS in Italy: Distribution of drugs in seized materials analysed in an Italian forensic laboratory in the period 2013-2015 Forensic Sci. Int. 265, 116-120 10.1016/j.forsciint.2016.01.037
27. Banister, S. D., Wilkinson, S. M., Longworth, M., Stuart, J., Apetz, N., English, K., Brooker, L., Goebel, C., Hibbs, D. E., Glass, M., Connor, M., McGregor, I. S., and Kassiou, M. (2013) The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse ACS Chem. Neurosci. 4, 1081-1092 10.1021/cn400035r
28. Banister, S. D., Stuart, J., Kevin, R. C., Edington, A., Longworth, M., Wilkinson, S. M., Beinat, C., Buchanan, A. S., Hibbs, D. E., Glass, M., Connor, M., McGregor, I. S., and Kassiou, M. (2015) Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135 ACS Chem. Neurosci. 6, 1445-1458 10.1021/acschemneuro.5b00107
29. Banister, S. D., Stuart, J., Conroy, T., Longworth, M., Manohar, M., Beinat, C., Wilkinson, S. M., Kevin, R. C., Hibbs, D. E., Glass, M., Connor, M., McGregor, I. S., and Kassiou, M. (2015) Structure-activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues Forensic Toxicol. 33, 355-366 10.1007/s11419-015-0282-9
30. Banister, S. D., Moir, M., Stuart, J., Kevin, R. C., Wood, K. E., Longworth, M., Wilkinson, S. M., Beinat, C., Buchanan, A. S., Glass, M., Connor, M., McGregor, I. S., and Kassiou, M. (2015) Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA ACS Chem. Neurosci. 6, 1546-1559 10.1021/acschemneuro.5b00112
31. Wilkinson, S. M., Banister, S. D., and Kassiou, M. (2015) Bioisosteric Fluorine in the Clandestine Design of Synthetic Cannabinoids Aust. J. Chem. 68, 4-8 10.1071/CH14198
32. Longworth, M., Banister, S. D., Mack, J. B. C., Glass, M., Connor, M., and Kassiou, M. (2016) The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities Forensic Toxicol. 34, 286 10.1007/s11419-016-0316-y
33. Drug Enforcement Administration, Department of Justice (2014) Schedules of controlled substances: temporary placement of four synthetic cannabinoids into Schedule I. Final order Fed. Reg. 79, 7577-7582
34. Drug Enforcement Administration, Department of Justice (2015) Schedules of controlled substances: temporary placement of three synthetic cannabinoids into schedule I. Final order Fed. Reg. 80, 5042-5047
35. European Monitoring Centre for Drugs and Drug Addiction (2015), EMCDDA-Europol 2014 Annual Report on the implementation of Council Decision 2005/387/JHA, Implementation reports, Publications Office of the European Union, Luxembourg.
36. European Monitoring Centre for Drugs and Drug Addiction (2015), New psychoactive substances in Europe. An update from the EU Early Warning System (March 2015), Publications Office of the European Union, Luxembourg.
37. Von Der Haar, J., Talebi, S., Ghobadi, F., Singh, S., Chirurgi, R., Rajeswari, P., Kalantari, H., and Hassen, G. W. (2016) Synthetic Cannabinoids and Their Effects on the Cardiovascular System J. Emerg. Med. 50, 258-262 10.1016/j.jemermed.2015.10.009
38. Louh, I. K. and Freeman, W. D. (2014) A 'spicy' encephalopathy: synthetic cannabinoids as cause of encephalopathy and seizure Crit. Care. 18, 553 10.1186/s13054-014-0553-6
39. Besli, G. E., Ikiz, M. A., Yildirim, S., and Saltik, S. (2015) Synthetic Cannabinoid Abuse in Adolescents: A Case Series J. Emerg. Med. 49, 644-650 10.1016/j.jemermed.2015.06.053
40. Gerostamoulos, D., Drummer, O. H., and Woodford, N. W. (2015) Deaths linked to synthetic cannabinoids Forensic Sci., Med., Pathol. 11, 478 10.1007/s12024-015-9669-5
41. Hermanns-Clausen, M., Kneisel, S., Szabo, B., and Auwarter, V. (2013) Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings Addiction. 108, 534-544 10.1111/j.1360-0443.2012.04078.x
42. Hermanns-Clausen, M., Kneisel, S., Hutter, M., Szabo, B., and Auwarter, V. (2013) Acute intoxication by synthetic cannabinoids - four case reports Drug Test. Anal. 5, 790-794 10.1002/dta.1483
43. Hermanns-Clausen, M., Kithinji, J., Spehl, M., Angerer, V., Franz, F., Eyer, F., and Auwarter, V. (2016) Adverse effects after the use of JWH-210-a case series from the EU Spice II plus project Drug Test. Anal. 10.1002/dta.1936
44. Hess, C., Stockhausen, S., Kernbach-Wighton, G., and Madea, B. (2015) Death due to diabetic ketoacidosis: Induction by the consumption of synthetic cannabinoids? Forensic Sci. Int. 257, e6-e11 10.1016/j.forsciint.2015.08.012
45. Lovett, C., Wood, D. M., and Dargan, P. I. (2015) Pharmacology and toxicology of the synthetic cannabinoid receptor agonists Réanimation. 24, 527-541 10.1007/s13546-015-1104-4
46. Mills, B., Yepes, A., and Nugent, K. (2015) Synthetic Cannabinoids Am. J. Med. Sci. 350, 59-62 10.1097/MAJ.0000000000000466
47. Muller, H. H., Kornhuber, J., and Sperling, W. (2015) The behavioral profile of spice and synthetic cannabinoids in humans Brain Res. Bull. 10.1016/j.brainresbull.2015.10.013
48. Obafemi, A. I., Kleinschmidt, K., Goto, C., and Fout, D. (2015) Cluster of Acute Toxicity from Ingestion of Synthetic Cannabinoid-Laced Brownies J. Med. Toxicol. 11, 426-429 10.1007/s13181-015-0482-z
49. van Amsterdam, J., Brunt, T., and van den Brink, W. (2015) The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects J. Psychopharmacol. 29, 254-263 10.1177/0269881114565142
50. Winstock, A., Lynskey, M., Borschmann, R., and Waldron, J. (2015) Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample J. Psychopharmacol. 29, 698-703 10.1177/0269881115574493
51. Castellanos, D. and Gralnik, L. M. (2016) Synthetic cannabinoids 2015: An update for pediatricians in clinical practice World J. Clin. Pediatr. 5, 16-24 10.5409/wjcp.v5.i1.16
52. Tait, R. J., Caldicott, D., Mountain, D., Hill, S. L., and Lenton, S. (2016) A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment Clin. Toxicol. 54, 1-13 10.3109/15563650.2015.1110590
53. Schifano, F., Orsolini, L., Papanti, D., and Corkery, J. (2016) NPS: Medical Consequences Associated with Their Intake. In Current Topics in Behavioral Neurosciences, pp 1-30, Springer International Publishing, Berlin.
54. Nacca, N., Vatti, D., Sullivan, R., Sud, P., Su, M., and Marraffa, J. (2013) The synthetic cannabinoid withdrawal syndrome J. Addict. Med. 7, 296-298 10.1097/ADM.0b013e31828e1881
55. Macfarlane, V. and Christie, G. (2015) Synthetic cannabinoid withdrawal: a new demand on detoxification services Drug Alcohol Rev. 34, 147-153 10.1111/dar.12225
56. Cooper, Z. D. (2016) Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal Curr. Psychiatry Rep. 18, 52 10.1007/s11920-016-0694-1
57. Van Hout, M. C. and Hearne, E. (2016) User Experiences of Development of Dependence on the Synthetic Cannabinoids, 5f-AKB48 and 5F-PB-22, and Subsequent Withdrawal Syndromes Int. J. Ment. Health Addict. 10.1007/s11469-016-9650-x
58. Sasaki, C., Saito, T., Shinozuka, T., Irie, W., Murakami, C., Maeda, K., Nakamaru, N., Oishi, M., Nakamura, S., and Kurihara, K. (2015) A case of death caused by abuse of a synthetic cannabinoid N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide Forensic Toxicol. 33, 165-169 10.1007/s11419-014-0246-5
59. Chung, H., Lee, J., and Kim, E. (2016) Trends of novel psychoactive substances (NPSs) and their fatal cases Forensic Toxicol. 34, 1-11 10.1007/s11419-015-0286-5
60. Kasper, A. M., Ridpath, A. D., Morrison, M., Olayinka, O., Parker, C., Galli, R., Cox, R., Preacely, N., Anderson, J., Kyle, P. B., Gerona, R., Martin, C., Schier, J., Wolkin, A., Dobbs, T., Arnold, J. K., and Chatham-Stephens, K. (2015) Notes from the Field: Severe Illness Associated with Reported Use of Synthetic Cannabinoids-Mississippi, April 2015 MMWR Morb Mortal. Wkly Rep. 64, 1121-1122 10.15585/mmwr.mm6439a7
61. Law, R., Schier, J., Martin, C., Chang, A., and Wolkin, A. (2015) Increase in Reported Adverse Health Effects Related to Synthetic Cannabinoid Use-United States, January-May 2015 MMWR Morb. Mortal. Wkly. Rep. 64, 618-619
62. Trecki, J., Gerona, R. R., and Schwartz, M. D. (2015) Synthetic Cannabinoid-Related Illnesses and Deaths N. Engl. J. Med. 373, 103-107 10.1056/NEJMp1505328
63. Labay, L. M., Caruso, J. L., Gilson, T. P., Phipps, R. J., Knight, L. D., Lemos, N. P., McIntyre, I. M., Stoppacher, R., Tormos, L. M., Wiens, A. L., Williams, E., and Logan, B. K. (2016) Synthetic cannabinoid drug use as a cause or contributory cause of death Forensic Sci. Int. 260, 31-39 10.1016/j.forsciint.2015.12.046
64. Klavž, J., Gorenjak, M., and Marinšek, M. (2016) Suicide attempt with a mix of synthetic cannabinoids and synthetic cathinones: Case report of non-fatal intoxication with AB-CHMINACA, AB-FUBINACA, alpha-PHP, alpha-PVP and 4-CMC Forensic Sci. Int. 265, 121-124 10.1016/j.forsciint.2016.01.018
65. Thornton, S. L., Bram, D., Milligan, D., and Gerona, R. (2015) Rhabdomyolysis associated with laboratory confirmed FUB-AMB use Clin. Toxicol. 53, 650-651
66. Hasegawa, K., Wurita, A., Minakata, K., Gonmori, K., Nozawa, H., Yamagishi, I., Watanabe, K., and Suzuki, O. (2015) Postmortem distribution of AB-CHMINACA, 5-fluoro-AMB, and diphenidine in body fluids and solid tissues in a fatal poisoning case: usefulness of adipose tissue for detection of the drugs in unchanged forms Forensic Toxicol. 33, 45-53 10.1007/s11419-014-0245-6
67. Shanks, K. G. and Behonick, G. S. (2016) Death after use of the synthetic cannabinoid 5F-AMB Forensic Sci. Int. 262, e21-4 10.1016/j.forsciint.2016.03.004
68. Hasegawa, K., Wurita, A., Minakata, K., Gonmori, K., Yamagishi, I., Nozawa, H., Watanabe, K., and Suzuki, O. (2015) Identification and quantitation of 5-fluoro-ADB, one of the most dangerous synthetic cannabinoids, in the stomach contents and solid tissues of a human cadaver and in some herbal products Forensic Toxicol. 33, 112-121 10.1007/s11419-014-0259-0
69. Adamowicz, P. (2016) Fatal intoxication with synthetic cannabinoid MDMB-CHMICA Forensic Sci. Int. 261, e5-e10 10.1016/j.forsciint.2016.02.024
70. Angerer, V., Franz, F., Schwarze, B., Moosmann, B., and Auwarter, V. (2016) Reply to 'Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICA' J. Anal. Toxicol. 40, 240-242 10.1093/jat/bkw004
71. Westin, A. A., Frost, J., Brede, W. R., Gundersen, P. O., Einvik, S., Aarset, H., and Slordal, L. (2016) Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICA J. Anal. Toxicol. 40, 86-87 10.1093/jat/bkv110
72. Shevyrin, V. A., Morzherin, Y. Y., Melkozerov, V. P., and Nevero, A. S. (2014) New Synthetic Cannabinoid-Methyl 2-{[1-(5-Fluoro-Pentyl)-3-Methyl-1H-Indol-3-Ylcarbonyl]-Amino}Butyrate-as a Designer Drug Chem. Heterocycl. Compd. 50, 583-586 10.1007/s10593-014-1511-6
73. Shevyrin, V., Melkozerov, V., Nevero, A., Eltsov, O., Shafran, Y., Morzherin, Y., and Lebedev, A. T. (2015) Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl group Anal. Bioanal. Chem. 407, 6301-6315 10.1007/s00216-015-8612-7
74. Akamatsu, S. and Yoshida, M. (2016) Fragmentation of synthetic cannabinoids with an isopropyl group or a tert-butyl group ionized by electron impact and electrospray J. Mass Spectrom. 51, 28-32 10.1002/jms.3722
75. Andernach, L., Pusch, S., Weber, C., Schollmeyer, D., Münster-Müller, S., Pütz, M., and Opatz, T. (2016) Absolute configuration of the synthetic cannabinoid MDMB-CHMICA with its chemical characteristics in illegal products Forensic Toxicol. 34, 344 10.1007/s11419-016-0321-1
76. Lobo Vicente, J., Chassaigne, H., Holland, M. V., Reniero, F., Kolar, K., Tirendi, S., Vandecasteele, I., Vinckier, I., and Guillou, C. (2016) Systematic analytical characterization of new psychoactive substances: A case study Forensic Sci. Int. 265, 107-115 10.1016/j.forsciint.2016.01.024
77. Andersson, M., Diao, X., Wohlfarth, A., Scheidweiler, K. B., and Huestis, M. A. (2016) Metabolic profiling of new synthetic cannabinoids AMB and 5F-AMB by human hepatocyte and liver microsome incubations and high-resolution mass spectrometry Rapid Commun. Mass Spectrom. 30, 1067-1078 10.1002/rcm.7538
78. Wiley, J. L., Compton, D. R., Dai, D., Lainton, J. A. H., Phillips, M., Huffman, J. W., and Martin, B. R. (1998) Structure-activity relationships of indole- and pyrrole-derived cannabinoids J. Pharmacol. Exp. Ther. 285, 995-1004
79. Wiley, J. L., Marusich, J. A., and Huffman, J. W. (2014) Moving around the molecule: Relationship between chemical structure and in vivo activity of synthetic cannabinoids Life Sci. 97, 55-63 10.1016/j.lfs.2013.09.011
80. Wiley, J. L., Lefever, T. W., Cortes, R. A., and Marusich, J. A. (2014) Cross-substitution of Delta9-tetrahydrocannabinol and JWH-018 in drug discrimination in rats Pharmacol., Biochem. Behav. 124, 123-128 10.1016/j.pbb.2014.05.016
81. Jarbe, T. U., Gifford, R. S., Zvonok, A., and Makriyannis, A. (2016) 9-Tetrahydrocannabinol discriminative stimulus effects of AM2201 and related aminoalkylindole analogs in rats Behav. Pharmacol. 27, 211-214 10.1097/FBP.0000000000000196
82. 8-THC during Acute and Chronic Administration to Conscious Rats Pharmacology 15, 65-72 10.1159/000136664
83. Wiley, J. L., Marusich, J. A., Martin, B. R., and Huffman, J. W. (2012) 1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice Drug Alcohol Depend. 123, 148-153 10.1016/j.drugalcdep.2011.11.001
84. Wiley, J. L., Marusich, J. A., Lefever, T. W., Grabenauer, M., Moore, K. N., and Thomas, B. F. (2013) Cannabinoids in disguise: Delta9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles Neuropharmacology 75, 145-154 10.1016/j.neuropharm.2013.07.022
85. Rinaldi-Carmona, M., Barth, F., Heaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D., Ferrara, P., Soubrié, P., Brelière, J. C., and Le Fur, G. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor FEBS Lett. 350, 240-244 10.1016/0014-5793(94)00773-X
86. Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J. M., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., Portier, M., Shire, D., Breliere, J. C., and Le Fur, G. L. (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor J. Pharmacol. Exp. Ther. 284, 644-650
87. Knapman, A., Santiago, M., and Connor, M. (2014) Buprenorphine signalling is compromised at the N40D polymorphism of the human mu opioid receptor in vitro Br. J. Pharmacol. 171, 4273-4288 10.1111/bph.12785
88. Knapman, A., Santiago, M., Du, Y. P., Bennallack, P. R., Christie, M. J., and Connor, M. (2013) A continuous, fluorescence-based assay of mu-opioid receptor activation in AtT-20 cells J. Biomol. Screening 18, 269-276 10.1177/1087057112461376